Boston Scientific Drastically Reduces Q1 Revenue Guidance
Add Boston Scientific (NYSE: BSX) to the list of companies scaling back or even eliminating their guidance in the wake of the SARS-CoV-2 coronavirus pandemic.
On Thursday, the healthcare-device specialist published an update for its investors, and one of the key points was a reduction in its outlook for its just-completed Q1 of fiscal 2020. It now believes GAAP revenue will be flat to "up slightly" on a year-over-year basis, with organic revenue falling by roughly 2% to 3%. It didn't provide any kind of forecast for profitability or update its annual guidance.
Image source: Boston Scientific.
Source Fool.com
